Corporate ActionMay 15, 2026, 04:13 PM
Lantern Pharma to Spin Off withZeta.ai AI Platform; Raises $4.4M
AI Summary
Lantern Pharma Inc. reported a reduced net loss of $3.33 million for Q1 2026, down from $4.54 million in Q1 2025, primarily due to lower R&D expenses. The company announced plans to spin off its withZeta.ai AI platform into an independent, newly listed business entity to secure dedicated funding and separate valuation. Additionally, Lantern Pharma completed a registered direct offering on May 14, 2026, raising approximately $4.4 million in gross proceeds, which is expected to fund operations until mid-Q1 2027, though substantial additional capital is needed to address going concern doubts.
Key Highlights
- Plans to spin off its withZeta.ai AI platform into an independent, newly listed business entity.
- Completed a registered direct offering on May 14, 2026, raising approximately $4.4 million in gross proceeds.
- Reported a net loss of $(3.33) million for Q1 2026, an improvement from $(4.54) million in Q1 2025.
- Net loss per share improved to $(0.30) in Q1 2026 from $(0.42) in Q1 2025.
- Research and development expenses decreased to $1.72 million in Q1 2026 from $3.26 million in Q1 2025.
- Working capital as of March 31, 2026, was approximately $3.28 million.
- Substantial doubt exists regarding the company's ability to continue as a going concern without additional funding.
- Existing cash and recent offering proceeds are expected to fund operations until mid-Q1 2027.
Price Impact
More from LTRN